Zelgen: Injectable ZG005 combined with Hydrochloride Gilteritinib Tablets and chemotherapy has received approval for clinical trials
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Zelgen announced that the company recently received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, approving the clinical trial of injectable ZG005 combined with Jikaxitinib hydrochloride tablets and chemotherapy for advanced solid tumors
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments